

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Motegrity (prucalopride)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

**\*Maryland Medicaid – See State Specific Mandates below**

Medications	Quantity Limit
Motegrity (prucalopride)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Motegrity (prucalopride) may be approved if the following criteria is met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has a diagnosis of chronic idiopathic constipation (CIC); **AND**
- III. The individual must have a previous trial of or insufficient response to two laxatives [e.g. polyethylene glycol (generic MiraLax), bisacodyl (Dulcolax), senna (Ex-lax)] (AGA 2013, 2019).

**Note:** Motegrity is contraindicated in individuals with an intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
Maryland		Trial of polyethylene glycol (PEG) is not required

### Key References:

1. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. 2013 Jan;144(1):211-7. Available from: [http://www.gastrojournal.org/article/S0016-5085\(12\)01545-4/pdf](http://www.gastrojournal.org/article/S0016-5085(12)01545-4/pdf). Accessed on: January 9, 2019.

PAGE 1 of 2 03/21/2019  
New Program Date 03/21/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0366-19

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

2. American Gastroenterological Association, Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. *Gastroenterology*. 2019 Jan;156(1): 218-226. Available from: [https://www.gastrojournal.org/article/S0016-5085\(18\)34782-6/pdf](https://www.gastrojournal.org/article/S0016-5085(18)34782-6/pdf). Accessed on: January 9, 2019.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 8, 2019.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0366-19